These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 10407949)
1. [Modern therapeutic possibilities in Parkinson disease]. Ludin HP Schweiz Med Wochenschr; 1999 May; 129(19):741-7. PubMed ID: 10407949 [TBL] [Abstract][Full Text] [Related]
2. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Deane KH; Spieker S; Clarke CE Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118 [TBL] [Abstract][Full Text] [Related]
3. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease. Sabaté M; Bosch A; Pedrós C; Figueras A Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327 [No Abstract] [Full Text] [Related]
5. New drugs for the treatment of Parkinson's disease. LeWitt PA Pharmacotherapy; 2000 Jan; 20(1 Pt 2):26S-32S. PubMed ID: 10641989 [TBL] [Abstract][Full Text] [Related]
6. New pharmacotherapy for Parkinson's disease. Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447 [TBL] [Abstract][Full Text] [Related]
7. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K; Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133 [TBL] [Abstract][Full Text] [Related]
8. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. Pahwa R J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613 [TBL] [Abstract][Full Text] [Related]
9. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397 [TBL] [Abstract][Full Text] [Related]
10. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease. Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184 [TBL] [Abstract][Full Text] [Related]
11. Tolcapone: a review of its use in the management of Parkinson's disease. Keating GM; Lyseng-Williamson KA CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329 [TBL] [Abstract][Full Text] [Related]
12. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Borges N Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899 [TBL] [Abstract][Full Text] [Related]
13. [A prospect of treatment for Parkinson's disease in the 21st century]. Yanagisawa N Nihon Rinsho; 2000 Oct; 58(10):1968-74. PubMed ID: 11068433 [TBL] [Abstract][Full Text] [Related]
14. 'Bad guys' among the antiparkinsonian drugs. Pirtosek Z Psychiatr Danub; 2009 Mar; 21(1):114-8. PubMed ID: 19270634 [TBL] [Abstract][Full Text] [Related]
15. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Arnold G; Kupsch A Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007 [TBL] [Abstract][Full Text] [Related]
16. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis. Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736 [TBL] [Abstract][Full Text] [Related]
17. Influence of COMT inhibition on levodopa pharmacology and therapy. Goetz CG Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519 [TBL] [Abstract][Full Text] [Related]
18. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Guay DR Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075 [TBL] [Abstract][Full Text] [Related]
19. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. Waters C J Am Geriatr Soc; 2000 Jun; 48(6):692-8. PubMed ID: 10855610 [TBL] [Abstract][Full Text] [Related]
20. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]